Global Analgesics Market research

Analgesics Comprehensive Study by Type (Opioid Alkaloids Analgesics {Morphina, Codeine, Other}, Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other}), Application (Nervous System, Digestive Tract, Cardiovascular System, Others), End User (Male, Female), Classes (Analgesic Combination, Cox-2 Inhibitors, Antimigraine Agents, Narcotic Analgesics, Narcotic analgesics., NSAIDs, Others) Players and Region - Global Market Outlook to 2025

Analgesics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Analgesics are used to getting relief from body pain. Analgesics is also known as a painkiller. Over-the-counter (OTC) (non-prescribed) analgesics that are generally used by the public are paracetamol, weak opioids such as codeine, and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin. Analgesics are broadly categorized with Nonopioid analgesics, Opioid analgesic Adjuvant analgesics. The Usage of Analgesics are increases day by day because of long seating job, pressure of work and all.This growth is primarily driven by Growing Number of Geriatric Population and Increasing Incidences of Cardiovascular Disease (CVD), Cancer, & Arthritis.

Globally, a noticeable market trend is evident Emerging Case of Body Pain from People who are Involved in Seating Jobs. Major Players, such as Bayer AG (Germany), Novartis AG (Switzerland), GlaxoSmithKline PLC (United Kingdom), Pfizer Inc (United States), Johnson & Johnson (United States), Reckitt Benckiser (United Kingdom), Endo Pharmaceuticals (Ireland), Bristol-Myers Squibb (United States), Eli Lilly and Company (United States) and Sanofi (France) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 20th February 2020, Baudax Bio, Inc. a pharmaceutical company focused on therapeutics for acute care settings, announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ANJESO (meloxicam injection), which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
On 21st November 2019, Baudax Bio, Inc. announced its launch as an independent, publicly-traded pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings.

Regulatory Insights:
"September 18, 2018, FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of new safety measures governing the use of immediate-release opioid analgesic medications."

Market Drivers
  • Growing Number of Geriatric Population
  • Increasing Incidences of Cardiovascular Disease (CVD), Cancer, & Arthritis

Market Trend
  • Emerging Case of Body Pain from People who are Involved in Seating Jobs

Restraints
  • Adverse Risk Associated with Heavy Dose of Analgesics Medication

Opportunities
Surging Spendings of People on Healthcare Products will Boost the Analgesics Market
Challenges
High Competition in the Analgesics Market

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
AMA Research & Media features not only specific market forecasts, but also include significant value-added commentary on:
Market Trends
Technological Trends and Innovations
Regulatory Trends & Policies
Market Maturity Indicators
Market Share Movements
Growth Drivers and Constraints
New Entrants into the Market & Entry/Exit Barriers
Consumer Demographics
Supporting Company Financial and Cash Flow Planning
Open Up New Markets
To Seize Powerful Market Opportunities
Key Decision in Planning and to Further Expand Market Share
Identify Key Business Segments, Market Proposition & Gap Analysis

Report Objectives / Segmentation Covered

By Type
  • Opioid Alkaloids Analgesics {Morphina, Codeine, Other}
  • Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other}
By Application
  • Nervous System
  • Digestive Tract
  • Cardiovascular System
  • Others
By End User
  • Male
  • Female

By Classes
  • Analgesic Combination
  • Cox-2 Inhibitors
  • Antimigraine Agents
  • Narcotic Analgesics
  • Narcotic analgesics.
  • NSAIDs
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Number of Geriatric Population
      • 3.2.2. Increasing Incidences of Cardiovascular Disease (CVD), Cancer, & Arthritis
    • 3.3. Market Challenges
      • 3.3.1. High Competition in the Analgesics Market
    • 3.4. Market Trends
      • 3.4.1. Emerging Case of Body Pain from People who are Involved in Seating Jobs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Analgesics, by Type, Application, End User, Classes and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Analgesics (Value)
      • 5.2.1. Global Analgesics by: Type (Value)
        • 5.2.1.1. Opioid Alkaloids Analgesics {Morphina, Codeine, Other}
        • 5.2.1.2. Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other}
      • 5.2.2. Global Analgesics by: Application (Value)
        • 5.2.2.1. Nervous System
        • 5.2.2.2. Digestive Tract
        • 5.2.2.3. Cardiovascular System
        • 5.2.2.4. Others
      • 5.2.3. Global Analgesics by: End User (Value)
        • 5.2.3.1. Male
        • 5.2.3.2. Female
      • 5.2.4. Global Analgesics by: Classes (Value)
        • 5.2.4.1. Analgesic Combination
        • 5.2.4.2. Cox-2 Inhibitors
        • 5.2.4.3. Antimigraine Agents
        • 5.2.4.4. Narcotic Analgesics
        • 5.2.4.5. Narcotic analgesics.
        • 5.2.4.6. NSAIDs
        • 5.2.4.7. Others
      • 5.2.5. Global Analgesics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Analgesics (Volume)
      • 5.3.1. Global Analgesics by: Type (Volume)
        • 5.3.1.1. Opioid Alkaloids Analgesics {Morphina, Codeine, Other}
        • 5.3.1.2. Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other}
      • 5.3.2. Global Analgesics by: Application (Volume)
        • 5.3.2.1. Nervous System
        • 5.3.2.2. Digestive Tract
        • 5.3.2.3. Cardiovascular System
        • 5.3.2.4. Others
      • 5.3.3. Global Analgesics by: End User (Volume)
        • 5.3.3.1. Male
        • 5.3.3.2. Female
      • 5.3.4. Global Analgesics by: Classes (Volume)
        • 5.3.4.1. Analgesic Combination
        • 5.3.4.2. Cox-2 Inhibitors
        • 5.3.4.3. Antimigraine Agents
        • 5.3.4.4. Narcotic Analgesics
        • 5.3.4.5. Narcotic analgesics.
        • 5.3.4.6. NSAIDs
        • 5.3.4.7. Others
      • 5.3.5. Global Analgesics Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Analgesics (Price)
      • 5.4.1. Global Analgesics by: Type (Price)
  • 6. Analgesics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Reckitt Benckiser (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Endo Pharmaceuticals (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Analgesics Sale, by Type, Application, End User, Classes and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Analgesics (Value)
      • 7.2.1. Global Analgesics by: Type (Value)
        • 7.2.1.1. Opioid Alkaloids Analgesics {Morphina, Codeine, Other}
        • 7.2.1.2. Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other}
      • 7.2.2. Global Analgesics by: Application (Value)
        • 7.2.2.1. Nervous System
        • 7.2.2.2. Digestive Tract
        • 7.2.2.3. Cardiovascular System
        • 7.2.2.4. Others
      • 7.2.3. Global Analgesics by: End User (Value)
        • 7.2.3.1. Male
        • 7.2.3.2. Female
      • 7.2.4. Global Analgesics by: Classes (Value)
        • 7.2.4.1. Analgesic Combination
        • 7.2.4.2. Cox-2 Inhibitors
        • 7.2.4.3. Antimigraine Agents
        • 7.2.4.4. Narcotic Analgesics
        • 7.2.4.5. Narcotic analgesics.
        • 7.2.4.6. NSAIDs
        • 7.2.4.7. Others
      • 7.2.5. Global Analgesics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Analgesics (Volume)
      • 7.3.1. Global Analgesics by: Type (Volume)
        • 7.3.1.1. Opioid Alkaloids Analgesics {Morphina, Codeine, Other}
        • 7.3.1.2. Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other}
      • 7.3.2. Global Analgesics by: Application (Volume)
        • 7.3.2.1. Nervous System
        • 7.3.2.2. Digestive Tract
        • 7.3.2.3. Cardiovascular System
        • 7.3.2.4. Others
      • 7.3.3. Global Analgesics by: End User (Volume)
        • 7.3.3.1. Male
        • 7.3.3.2. Female
      • 7.3.4. Global Analgesics by: Classes (Volume)
        • 7.3.4.1. Analgesic Combination
        • 7.3.4.2. Cox-2 Inhibitors
        • 7.3.4.3. Antimigraine Agents
        • 7.3.4.4. Narcotic Analgesics
        • 7.3.4.5. Narcotic analgesics.
        • 7.3.4.6. NSAIDs
        • 7.3.4.7. Others
      • 7.3.5. Global Analgesics Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Analgesics (Price)
      • 7.4.1. Global Analgesics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Analgesics: by Type(USD Million)
  • Table 2. Analgesics Opioid Alkaloids Analgesics {Morphina, Codeine, Other} , by Region USD Million (2014-2019)
  • Table 3. Analgesics Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other} , by Region USD Million (2014-2019)
  • Table 4. Analgesics: by Application(USD Million)
  • Table 5. Analgesics Nervous System , by Region USD Million (2014-2019)
  • Table 6. Analgesics Digestive Tract , by Region USD Million (2014-2019)
  • Table 7. Analgesics Cardiovascular System , by Region USD Million (2014-2019)
  • Table 8. Analgesics Others , by Region USD Million (2014-2019)
  • Table 9. Analgesics: by End User(USD Million)
  • Table 10. Analgesics Male , by Region USD Million (2014-2019)
  • Table 11. Analgesics Female , by Region USD Million (2014-2019)
  • Table 12. Analgesics: by Classes(USD Million)
  • Table 13. Analgesics Analgesic Combination , by Region USD Million (2014-2019)
  • Table 14. Analgesics Cox-2 Inhibitors , by Region USD Million (2014-2019)
  • Table 15. Analgesics Antimigraine Agents , by Region USD Million (2014-2019)
  • Table 16. Analgesics Narcotic Analgesics , by Region USD Million (2014-2019)
  • Table 17. Analgesics Narcotic analgesics. , by Region USD Million (2014-2019)
  • Table 18. Analgesics NSAIDs , by Region USD Million (2014-2019)
  • Table 19. Analgesics Others , by Region USD Million (2014-2019)
  • Table 20. South America Analgesics, by Country USD Million (2014-2019)
  • Table 21. South America Analgesics, by Type USD Million (2014-2019)
  • Table 22. South America Analgesics, by Application USD Million (2014-2019)
  • Table 23. South America Analgesics, by End User USD Million (2014-2019)
  • Table 24. South America Analgesics, by Classes USD Million (2014-2019)
  • Table 25. Brazil Analgesics, by Type USD Million (2014-2019)
  • Table 26. Brazil Analgesics, by Application USD Million (2014-2019)
  • Table 27. Brazil Analgesics, by End User USD Million (2014-2019)
  • Table 28. Brazil Analgesics, by Classes USD Million (2014-2019)
  • Table 29. Argentina Analgesics, by Type USD Million (2014-2019)
  • Table 30. Argentina Analgesics, by Application USD Million (2014-2019)
  • Table 31. Argentina Analgesics, by End User USD Million (2014-2019)
  • Table 32. Argentina Analgesics, by Classes USD Million (2014-2019)
  • Table 33. Rest of South America Analgesics, by Type USD Million (2014-2019)
  • Table 34. Rest of South America Analgesics, by Application USD Million (2014-2019)
  • Table 35. Rest of South America Analgesics, by End User USD Million (2014-2019)
  • Table 36. Rest of South America Analgesics, by Classes USD Million (2014-2019)
  • Table 37. Asia Pacific Analgesics, by Country USD Million (2014-2019)
  • Table 38. Asia Pacific Analgesics, by Type USD Million (2014-2019)
  • Table 39. Asia Pacific Analgesics, by Application USD Million (2014-2019)
  • Table 40. Asia Pacific Analgesics, by End User USD Million (2014-2019)
  • Table 41. Asia Pacific Analgesics, by Classes USD Million (2014-2019)
  • Table 42. China Analgesics, by Type USD Million (2014-2019)
  • Table 43. China Analgesics, by Application USD Million (2014-2019)
  • Table 44. China Analgesics, by End User USD Million (2014-2019)
  • Table 45. China Analgesics, by Classes USD Million (2014-2019)
  • Table 46. Japan Analgesics, by Type USD Million (2014-2019)
  • Table 47. Japan Analgesics, by Application USD Million (2014-2019)
  • Table 48. Japan Analgesics, by End User USD Million (2014-2019)
  • Table 49. Japan Analgesics, by Classes USD Million (2014-2019)
  • Table 50. India Analgesics, by Type USD Million (2014-2019)
  • Table 51. India Analgesics, by Application USD Million (2014-2019)
  • Table 52. India Analgesics, by End User USD Million (2014-2019)
  • Table 53. India Analgesics, by Classes USD Million (2014-2019)
  • Table 54. South Korea Analgesics, by Type USD Million (2014-2019)
  • Table 55. South Korea Analgesics, by Application USD Million (2014-2019)
  • Table 56. South Korea Analgesics, by End User USD Million (2014-2019)
  • Table 57. South Korea Analgesics, by Classes USD Million (2014-2019)
  • Table 58. Taiwan Analgesics, by Type USD Million (2014-2019)
  • Table 59. Taiwan Analgesics, by Application USD Million (2014-2019)
  • Table 60. Taiwan Analgesics, by End User USD Million (2014-2019)
  • Table 61. Taiwan Analgesics, by Classes USD Million (2014-2019)
  • Table 62. Australia Analgesics, by Type USD Million (2014-2019)
  • Table 63. Australia Analgesics, by Application USD Million (2014-2019)
  • Table 64. Australia Analgesics, by End User USD Million (2014-2019)
  • Table 65. Australia Analgesics, by Classes USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Analgesics, by Type USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Analgesics, by Application USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Analgesics, by End User USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Analgesics, by Classes USD Million (2014-2019)
  • Table 70. Europe Analgesics, by Country USD Million (2014-2019)
  • Table 71. Europe Analgesics, by Type USD Million (2014-2019)
  • Table 72. Europe Analgesics, by Application USD Million (2014-2019)
  • Table 73. Europe Analgesics, by End User USD Million (2014-2019)
  • Table 74. Europe Analgesics, by Classes USD Million (2014-2019)
  • Table 75. Germany Analgesics, by Type USD Million (2014-2019)
  • Table 76. Germany Analgesics, by Application USD Million (2014-2019)
  • Table 77. Germany Analgesics, by End User USD Million (2014-2019)
  • Table 78. Germany Analgesics, by Classes USD Million (2014-2019)
  • Table 79. France Analgesics, by Type USD Million (2014-2019)
  • Table 80. France Analgesics, by Application USD Million (2014-2019)
  • Table 81. France Analgesics, by End User USD Million (2014-2019)
  • Table 82. France Analgesics, by Classes USD Million (2014-2019)
  • Table 83. Italy Analgesics, by Type USD Million (2014-2019)
  • Table 84. Italy Analgesics, by Application USD Million (2014-2019)
  • Table 85. Italy Analgesics, by End User USD Million (2014-2019)
  • Table 86. Italy Analgesics, by Classes USD Million (2014-2019)
  • Table 87. United Kingdom Analgesics, by Type USD Million (2014-2019)
  • Table 88. United Kingdom Analgesics, by Application USD Million (2014-2019)
  • Table 89. United Kingdom Analgesics, by End User USD Million (2014-2019)
  • Table 90. United Kingdom Analgesics, by Classes USD Million (2014-2019)
  • Table 91. Netherlands Analgesics, by Type USD Million (2014-2019)
  • Table 92. Netherlands Analgesics, by Application USD Million (2014-2019)
  • Table 93. Netherlands Analgesics, by End User USD Million (2014-2019)
  • Table 94. Netherlands Analgesics, by Classes USD Million (2014-2019)
  • Table 95. Rest of Europe Analgesics, by Type USD Million (2014-2019)
  • Table 96. Rest of Europe Analgesics, by Application USD Million (2014-2019)
  • Table 97. Rest of Europe Analgesics, by End User USD Million (2014-2019)
  • Table 98. Rest of Europe Analgesics, by Classes USD Million (2014-2019)
  • Table 99. MEA Analgesics, by Country USD Million (2014-2019)
  • Table 100. MEA Analgesics, by Type USD Million (2014-2019)
  • Table 101. MEA Analgesics, by Application USD Million (2014-2019)
  • Table 102. MEA Analgesics, by End User USD Million (2014-2019)
  • Table 103. MEA Analgesics, by Classes USD Million (2014-2019)
  • Table 104. Middle East Analgesics, by Type USD Million (2014-2019)
  • Table 105. Middle East Analgesics, by Application USD Million (2014-2019)
  • Table 106. Middle East Analgesics, by End User USD Million (2014-2019)
  • Table 107. Middle East Analgesics, by Classes USD Million (2014-2019)
  • Table 108. Africa Analgesics, by Type USD Million (2014-2019)
  • Table 109. Africa Analgesics, by Application USD Million (2014-2019)
  • Table 110. Africa Analgesics, by End User USD Million (2014-2019)
  • Table 111. Africa Analgesics, by Classes USD Million (2014-2019)
  • Table 112. North America Analgesics, by Country USD Million (2014-2019)
  • Table 113. North America Analgesics, by Type USD Million (2014-2019)
  • Table 114. North America Analgesics, by Application USD Million (2014-2019)
  • Table 115. North America Analgesics, by End User USD Million (2014-2019)
  • Table 116. North America Analgesics, by Classes USD Million (2014-2019)
  • Table 117. United States Analgesics, by Type USD Million (2014-2019)
  • Table 118. United States Analgesics, by Application USD Million (2014-2019)
  • Table 119. United States Analgesics, by End User USD Million (2014-2019)
  • Table 120. United States Analgesics, by Classes USD Million (2014-2019)
  • Table 121. Canada Analgesics, by Type USD Million (2014-2019)
  • Table 122. Canada Analgesics, by Application USD Million (2014-2019)
  • Table 123. Canada Analgesics, by End User USD Million (2014-2019)
  • Table 124. Canada Analgesics, by Classes USD Million (2014-2019)
  • Table 125. Mexico Analgesics, by Type USD Million (2014-2019)
  • Table 126. Mexico Analgesics, by Application USD Million (2014-2019)
  • Table 127. Mexico Analgesics, by End User USD Million (2014-2019)
  • Table 128. Mexico Analgesics, by Classes USD Million (2014-2019)
  • Table 129. Analgesics Sales: by Type(K Units)
  • Table 130. Analgesics Sales Opioid Alkaloids Analgesics {Morphina, Codeine, Other} , by Region K Units (2014-2019)
  • Table 131. Analgesics Sales Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other} , by Region K Units (2014-2019)
  • Table 132. Analgesics Sales: by Application(K Units)
  • Table 133. Analgesics Sales Nervous System , by Region K Units (2014-2019)
  • Table 134. Analgesics Sales Digestive Tract , by Region K Units (2014-2019)
  • Table 135. Analgesics Sales Cardiovascular System , by Region K Units (2014-2019)
  • Table 136. Analgesics Sales Others , by Region K Units (2014-2019)
  • Table 137. Analgesics Sales: by End User(K Units)
  • Table 138. Analgesics Sales Male , by Region K Units (2014-2019)
  • Table 139. Analgesics Sales Female , by Region K Units (2014-2019)
  • Table 140. Analgesics Sales: by Classes(K Units)
  • Table 141. Analgesics Sales Analgesic Combination , by Region K Units (2014-2019)
  • Table 142. Analgesics Sales Cox-2 Inhibitors , by Region K Units (2014-2019)
  • Table 143. Analgesics Sales Antimigraine Agents , by Region K Units (2014-2019)
  • Table 144. Analgesics Sales Narcotic Analgesics , by Region K Units (2014-2019)
  • Table 145. Analgesics Sales Narcotic analgesics. , by Region K Units (2014-2019)
  • Table 146. Analgesics Sales NSAIDs , by Region K Units (2014-2019)
  • Table 147. Analgesics Sales Others , by Region K Units (2014-2019)
  • Table 148. South America Analgesics Sales, by Country K Units (2014-2019)
  • Table 149. South America Analgesics Sales, by Type K Units (2014-2019)
  • Table 150. South America Analgesics Sales, by Application K Units (2014-2019)
  • Table 151. South America Analgesics Sales, by End User K Units (2014-2019)
  • Table 152. South America Analgesics Sales, by Classes K Units (2014-2019)
  • Table 153. Brazil Analgesics Sales, by Type K Units (2014-2019)
  • Table 154. Brazil Analgesics Sales, by Application K Units (2014-2019)
  • Table 155. Brazil Analgesics Sales, by End User K Units (2014-2019)
  • Table 156. Brazil Analgesics Sales, by Classes K Units (2014-2019)
  • Table 157. Argentina Analgesics Sales, by Type K Units (2014-2019)
  • Table 158. Argentina Analgesics Sales, by Application K Units (2014-2019)
  • Table 159. Argentina Analgesics Sales, by End User K Units (2014-2019)
  • Table 160. Argentina Analgesics Sales, by Classes K Units (2014-2019)
  • Table 161. Rest of South America Analgesics Sales, by Type K Units (2014-2019)
  • Table 162. Rest of South America Analgesics Sales, by Application K Units (2014-2019)
  • Table 163. Rest of South America Analgesics Sales, by End User K Units (2014-2019)
  • Table 164. Rest of South America Analgesics Sales, by Classes K Units (2014-2019)
  • Table 165. Asia Pacific Analgesics Sales, by Country K Units (2014-2019)
  • Table 166. Asia Pacific Analgesics Sales, by Type K Units (2014-2019)
  • Table 167. Asia Pacific Analgesics Sales, by Application K Units (2014-2019)
  • Table 168. Asia Pacific Analgesics Sales, by End User K Units (2014-2019)
  • Table 169. Asia Pacific Analgesics Sales, by Classes K Units (2014-2019)
  • Table 170. China Analgesics Sales, by Type K Units (2014-2019)
  • Table 171. China Analgesics Sales, by Application K Units (2014-2019)
  • Table 172. China Analgesics Sales, by End User K Units (2014-2019)
  • Table 173. China Analgesics Sales, by Classes K Units (2014-2019)
  • Table 174. Japan Analgesics Sales, by Type K Units (2014-2019)
  • Table 175. Japan Analgesics Sales, by Application K Units (2014-2019)
  • Table 176. Japan Analgesics Sales, by End User K Units (2014-2019)
  • Table 177. Japan Analgesics Sales, by Classes K Units (2014-2019)
  • Table 178. India Analgesics Sales, by Type K Units (2014-2019)
  • Table 179. India Analgesics Sales, by Application K Units (2014-2019)
  • Table 180. India Analgesics Sales, by End User K Units (2014-2019)
  • Table 181. India Analgesics Sales, by Classes K Units (2014-2019)
  • Table 182. South Korea Analgesics Sales, by Type K Units (2014-2019)
  • Table 183. South Korea Analgesics Sales, by Application K Units (2014-2019)
  • Table 184. South Korea Analgesics Sales, by End User K Units (2014-2019)
  • Table 185. South Korea Analgesics Sales, by Classes K Units (2014-2019)
  • Table 186. Taiwan Analgesics Sales, by Type K Units (2014-2019)
  • Table 187. Taiwan Analgesics Sales, by Application K Units (2014-2019)
  • Table 188. Taiwan Analgesics Sales, by End User K Units (2014-2019)
  • Table 189. Taiwan Analgesics Sales, by Classes K Units (2014-2019)
  • Table 190. Australia Analgesics Sales, by Type K Units (2014-2019)
  • Table 191. Australia Analgesics Sales, by Application K Units (2014-2019)
  • Table 192. Australia Analgesics Sales, by End User K Units (2014-2019)
  • Table 193. Australia Analgesics Sales, by Classes K Units (2014-2019)
  • Table 194. Rest of Asia-Pacific Analgesics Sales, by Type K Units (2014-2019)
  • Table 195. Rest of Asia-Pacific Analgesics Sales, by Application K Units (2014-2019)
  • Table 196. Rest of Asia-Pacific Analgesics Sales, by End User K Units (2014-2019)
  • Table 197. Rest of Asia-Pacific Analgesics Sales, by Classes K Units (2014-2019)
  • Table 198. Europe Analgesics Sales, by Country K Units (2014-2019)
  • Table 199. Europe Analgesics Sales, by Type K Units (2014-2019)
  • Table 200. Europe Analgesics Sales, by Application K Units (2014-2019)
  • Table 201. Europe Analgesics Sales, by End User K Units (2014-2019)
  • Table 202. Europe Analgesics Sales, by Classes K Units (2014-2019)
  • Table 203. Germany Analgesics Sales, by Type K Units (2014-2019)
  • Table 204. Germany Analgesics Sales, by Application K Units (2014-2019)
  • Table 205. Germany Analgesics Sales, by End User K Units (2014-2019)
  • Table 206. Germany Analgesics Sales, by Classes K Units (2014-2019)
  • Table 207. France Analgesics Sales, by Type K Units (2014-2019)
  • Table 208. France Analgesics Sales, by Application K Units (2014-2019)
  • Table 209. France Analgesics Sales, by End User K Units (2014-2019)
  • Table 210. France Analgesics Sales, by Classes K Units (2014-2019)
  • Table 211. Italy Analgesics Sales, by Type K Units (2014-2019)
  • Table 212. Italy Analgesics Sales, by Application K Units (2014-2019)
  • Table 213. Italy Analgesics Sales, by End User K Units (2014-2019)
  • Table 214. Italy Analgesics Sales, by Classes K Units (2014-2019)
  • Table 215. United Kingdom Analgesics Sales, by Type K Units (2014-2019)
  • Table 216. United Kingdom Analgesics Sales, by Application K Units (2014-2019)
  • Table 217. United Kingdom Analgesics Sales, by End User K Units (2014-2019)
  • Table 218. United Kingdom Analgesics Sales, by Classes K Units (2014-2019)
  • Table 219. Netherlands Analgesics Sales, by Type K Units (2014-2019)
  • Table 220. Netherlands Analgesics Sales, by Application K Units (2014-2019)
  • Table 221. Netherlands Analgesics Sales, by End User K Units (2014-2019)
  • Table 222. Netherlands Analgesics Sales, by Classes K Units (2014-2019)
  • Table 223. Rest of Europe Analgesics Sales, by Type K Units (2014-2019)
  • Table 224. Rest of Europe Analgesics Sales, by Application K Units (2014-2019)
  • Table 225. Rest of Europe Analgesics Sales, by End User K Units (2014-2019)
  • Table 226. Rest of Europe Analgesics Sales, by Classes K Units (2014-2019)
  • Table 227. MEA Analgesics Sales, by Country K Units (2014-2019)
  • Table 228. MEA Analgesics Sales, by Type K Units (2014-2019)
  • Table 229. MEA Analgesics Sales, by Application K Units (2014-2019)
  • Table 230. MEA Analgesics Sales, by End User K Units (2014-2019)
  • Table 231. MEA Analgesics Sales, by Classes K Units (2014-2019)
  • Table 232. Middle East Analgesics Sales, by Type K Units (2014-2019)
  • Table 233. Middle East Analgesics Sales, by Application K Units (2014-2019)
  • Table 234. Middle East Analgesics Sales, by End User K Units (2014-2019)
  • Table 235. Middle East Analgesics Sales, by Classes K Units (2014-2019)
  • Table 236. Africa Analgesics Sales, by Type K Units (2014-2019)
  • Table 237. Africa Analgesics Sales, by Application K Units (2014-2019)
  • Table 238. Africa Analgesics Sales, by End User K Units (2014-2019)
  • Table 239. Africa Analgesics Sales, by Classes K Units (2014-2019)
  • Table 240. North America Analgesics Sales, by Country K Units (2014-2019)
  • Table 241. North America Analgesics Sales, by Type K Units (2014-2019)
  • Table 242. North America Analgesics Sales, by Application K Units (2014-2019)
  • Table 243. North America Analgesics Sales, by End User K Units (2014-2019)
  • Table 244. North America Analgesics Sales, by Classes K Units (2014-2019)
  • Table 245. United States Analgesics Sales, by Type K Units (2014-2019)
  • Table 246. United States Analgesics Sales, by Application K Units (2014-2019)
  • Table 247. United States Analgesics Sales, by End User K Units (2014-2019)
  • Table 248. United States Analgesics Sales, by Classes K Units (2014-2019)
  • Table 249. Canada Analgesics Sales, by Type K Units (2014-2019)
  • Table 250. Canada Analgesics Sales, by Application K Units (2014-2019)
  • Table 251. Canada Analgesics Sales, by End User K Units (2014-2019)
  • Table 252. Canada Analgesics Sales, by Classes K Units (2014-2019)
  • Table 253. Mexico Analgesics Sales, by Type K Units (2014-2019)
  • Table 254. Mexico Analgesics Sales, by Application K Units (2014-2019)
  • Table 255. Mexico Analgesics Sales, by End User K Units (2014-2019)
  • Table 256. Mexico Analgesics Sales, by Classes K Units (2014-2019)
  • Table 257. Analgesics: by Type(USD/Units)
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Analgesics: by Type(USD Million)
  • Table 269. Analgesics Opioid Alkaloids Analgesics {Morphina, Codeine, Other} , by Region USD Million (2020-2025)
  • Table 270. Analgesics Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other} , by Region USD Million (2020-2025)
  • Table 271. Analgesics: by Application(USD Million)
  • Table 272. Analgesics Nervous System , by Region USD Million (2020-2025)
  • Table 273. Analgesics Digestive Tract , by Region USD Million (2020-2025)
  • Table 274. Analgesics Cardiovascular System , by Region USD Million (2020-2025)
  • Table 275. Analgesics Others , by Region USD Million (2020-2025)
  • Table 276. Analgesics: by End User(USD Million)
  • Table 277. Analgesics Male , by Region USD Million (2020-2025)
  • Table 278. Analgesics Female , by Region USD Million (2020-2025)
  • Table 279. Analgesics: by Classes(USD Million)
  • Table 280. Analgesics Analgesic Combination , by Region USD Million (2020-2025)
  • Table 281. Analgesics Cox-2 Inhibitors , by Region USD Million (2020-2025)
  • Table 282. Analgesics Antimigraine Agents , by Region USD Million (2020-2025)
  • Table 283. Analgesics Narcotic Analgesics , by Region USD Million (2020-2025)
  • Table 284. Analgesics Narcotic analgesics. , by Region USD Million (2020-2025)
  • Table 285. Analgesics NSAIDs , by Region USD Million (2020-2025)
  • Table 286. Analgesics Others , by Region USD Million (2020-2025)
  • Table 287. South America Analgesics, by Country USD Million (2020-2025)
  • Table 288. South America Analgesics, by Type USD Million (2020-2025)
  • Table 289. South America Analgesics, by Application USD Million (2020-2025)
  • Table 290. South America Analgesics, by End User USD Million (2020-2025)
  • Table 291. South America Analgesics, by Classes USD Million (2020-2025)
  • Table 292. Brazil Analgesics, by Type USD Million (2020-2025)
  • Table 293. Brazil Analgesics, by Application USD Million (2020-2025)
  • Table 294. Brazil Analgesics, by End User USD Million (2020-2025)
  • Table 295. Brazil Analgesics, by Classes USD Million (2020-2025)
  • Table 296. Argentina Analgesics, by Type USD Million (2020-2025)
  • Table 297. Argentina Analgesics, by Application USD Million (2020-2025)
  • Table 298. Argentina Analgesics, by End User USD Million (2020-2025)
  • Table 299. Argentina Analgesics, by Classes USD Million (2020-2025)
  • Table 300. Rest of South America Analgesics, by Type USD Million (2020-2025)
  • Table 301. Rest of South America Analgesics, by Application USD Million (2020-2025)
  • Table 302. Rest of South America Analgesics, by End User USD Million (2020-2025)
  • Table 303. Rest of South America Analgesics, by Classes USD Million (2020-2025)
  • Table 304. Asia Pacific Analgesics, by Country USD Million (2020-2025)
  • Table 305. Asia Pacific Analgesics, by Type USD Million (2020-2025)
  • Table 306. Asia Pacific Analgesics, by Application USD Million (2020-2025)
  • Table 307. Asia Pacific Analgesics, by End User USD Million (2020-2025)
  • Table 308. Asia Pacific Analgesics, by Classes USD Million (2020-2025)
  • Table 309. China Analgesics, by Type USD Million (2020-2025)
  • Table 310. China Analgesics, by Application USD Million (2020-2025)
  • Table 311. China Analgesics, by End User USD Million (2020-2025)
  • Table 312. China Analgesics, by Classes USD Million (2020-2025)
  • Table 313. Japan Analgesics, by Type USD Million (2020-2025)
  • Table 314. Japan Analgesics, by Application USD Million (2020-2025)
  • Table 315. Japan Analgesics, by End User USD Million (2020-2025)
  • Table 316. Japan Analgesics, by Classes USD Million (2020-2025)
  • Table 317. India Analgesics, by Type USD Million (2020-2025)
  • Table 318. India Analgesics, by Application USD Million (2020-2025)
  • Table 319. India Analgesics, by End User USD Million (2020-2025)
  • Table 320. India Analgesics, by Classes USD Million (2020-2025)
  • Table 321. South Korea Analgesics, by Type USD Million (2020-2025)
  • Table 322. South Korea Analgesics, by Application USD Million (2020-2025)
  • Table 323. South Korea Analgesics, by End User USD Million (2020-2025)
  • Table 324. South Korea Analgesics, by Classes USD Million (2020-2025)
  • Table 325. Taiwan Analgesics, by Type USD Million (2020-2025)
  • Table 326. Taiwan Analgesics, by Application USD Million (2020-2025)
  • Table 327. Taiwan Analgesics, by End User USD Million (2020-2025)
  • Table 328. Taiwan Analgesics, by Classes USD Million (2020-2025)
  • Table 329. Australia Analgesics, by Type USD Million (2020-2025)
  • Table 330. Australia Analgesics, by Application USD Million (2020-2025)
  • Table 331. Australia Analgesics, by End User USD Million (2020-2025)
  • Table 332. Australia Analgesics, by Classes USD Million (2020-2025)
  • Table 333. Rest of Asia-Pacific Analgesics, by Type USD Million (2020-2025)
  • Table 334. Rest of Asia-Pacific Analgesics, by Application USD Million (2020-2025)
  • Table 335. Rest of Asia-Pacific Analgesics, by End User USD Million (2020-2025)
  • Table 336. Rest of Asia-Pacific Analgesics, by Classes USD Million (2020-2025)
  • Table 337. Europe Analgesics, by Country USD Million (2020-2025)
  • Table 338. Europe Analgesics, by Type USD Million (2020-2025)
  • Table 339. Europe Analgesics, by Application USD Million (2020-2025)
  • Table 340. Europe Analgesics, by End User USD Million (2020-2025)
  • Table 341. Europe Analgesics, by Classes USD Million (2020-2025)
  • Table 342. Germany Analgesics, by Type USD Million (2020-2025)
  • Table 343. Germany Analgesics, by Application USD Million (2020-2025)
  • Table 344. Germany Analgesics, by End User USD Million (2020-2025)
  • Table 345. Germany Analgesics, by Classes USD Million (2020-2025)
  • Table 346. France Analgesics, by Type USD Million (2020-2025)
  • Table 347. France Analgesics, by Application USD Million (2020-2025)
  • Table 348. France Analgesics, by End User USD Million (2020-2025)
  • Table 349. France Analgesics, by Classes USD Million (2020-2025)
  • Table 350. Italy Analgesics, by Type USD Million (2020-2025)
  • Table 351. Italy Analgesics, by Application USD Million (2020-2025)
  • Table 352. Italy Analgesics, by End User USD Million (2020-2025)
  • Table 353. Italy Analgesics, by Classes USD Million (2020-2025)
  • Table 354. United Kingdom Analgesics, by Type USD Million (2020-2025)
  • Table 355. United Kingdom Analgesics, by Application USD Million (2020-2025)
  • Table 356. United Kingdom Analgesics, by End User USD Million (2020-2025)
  • Table 357. United Kingdom Analgesics, by Classes USD Million (2020-2025)
  • Table 358. Netherlands Analgesics, by Type USD Million (2020-2025)
  • Table 359. Netherlands Analgesics, by Application USD Million (2020-2025)
  • Table 360. Netherlands Analgesics, by End User USD Million (2020-2025)
  • Table 361. Netherlands Analgesics, by Classes USD Million (2020-2025)
  • Table 362. Rest of Europe Analgesics, by Type USD Million (2020-2025)
  • Table 363. Rest of Europe Analgesics, by Application USD Million (2020-2025)
  • Table 364. Rest of Europe Analgesics, by End User USD Million (2020-2025)
  • Table 365. Rest of Europe Analgesics, by Classes USD Million (2020-2025)
  • Table 366. MEA Analgesics, by Country USD Million (2020-2025)
  • Table 367. MEA Analgesics, by Type USD Million (2020-2025)
  • Table 368. MEA Analgesics, by Application USD Million (2020-2025)
  • Table 369. MEA Analgesics, by End User USD Million (2020-2025)
  • Table 370. MEA Analgesics, by Classes USD Million (2020-2025)
  • Table 371. Middle East Analgesics, by Type USD Million (2020-2025)
  • Table 372. Middle East Analgesics, by Application USD Million (2020-2025)
  • Table 373. Middle East Analgesics, by End User USD Million (2020-2025)
  • Table 374. Middle East Analgesics, by Classes USD Million (2020-2025)
  • Table 375. Africa Analgesics, by Type USD Million (2020-2025)
  • Table 376. Africa Analgesics, by Application USD Million (2020-2025)
  • Table 377. Africa Analgesics, by End User USD Million (2020-2025)
  • Table 378. Africa Analgesics, by Classes USD Million (2020-2025)
  • Table 379. North America Analgesics, by Country USD Million (2020-2025)
  • Table 380. North America Analgesics, by Type USD Million (2020-2025)
  • Table 381. North America Analgesics, by Application USD Million (2020-2025)
  • Table 382. North America Analgesics, by End User USD Million (2020-2025)
  • Table 383. North America Analgesics, by Classes USD Million (2020-2025)
  • Table 384. United States Analgesics, by Type USD Million (2020-2025)
  • Table 385. United States Analgesics, by Application USD Million (2020-2025)
  • Table 386. United States Analgesics, by End User USD Million (2020-2025)
  • Table 387. United States Analgesics, by Classes USD Million (2020-2025)
  • Table 388. Canada Analgesics, by Type USD Million (2020-2025)
  • Table 389. Canada Analgesics, by Application USD Million (2020-2025)
  • Table 390. Canada Analgesics, by End User USD Million (2020-2025)
  • Table 391. Canada Analgesics, by Classes USD Million (2020-2025)
  • Table 392. Mexico Analgesics, by Type USD Million (2020-2025)
  • Table 393. Mexico Analgesics, by Application USD Million (2020-2025)
  • Table 394. Mexico Analgesics, by End User USD Million (2020-2025)
  • Table 395. Mexico Analgesics, by Classes USD Million (2020-2025)
  • Table 396. Analgesics Sales: by Type(K Units)
  • Table 397. Analgesics Sales Opioid Alkaloids Analgesics {Morphina, Codeine, Other} , by Region K Units (2020-2025)
  • Table 398. Analgesics Sales Synthetic Analgesics {Pethidine, Alphaprodine, Adanon, Other} , by Region K Units (2020-2025)
  • Table 399. Analgesics Sales: by Application(K Units)
  • Table 400. Analgesics Sales Nervous System , by Region K Units (2020-2025)
  • Table 401. Analgesics Sales Digestive Tract , by Region K Units (2020-2025)
  • Table 402. Analgesics Sales Cardiovascular System , by Region K Units (2020-2025)
  • Table 403. Analgesics Sales Others , by Region K Units (2020-2025)
  • Table 404. Analgesics Sales: by End User(K Units)
  • Table 405. Analgesics Sales Male , by Region K Units (2020-2025)
  • Table 406. Analgesics Sales Female , by Region K Units (2020-2025)
  • Table 407. Analgesics Sales: by Classes(K Units)
  • Table 408. Analgesics Sales Analgesic Combination , by Region K Units (2020-2025)
  • Table 409. Analgesics Sales Cox-2 Inhibitors , by Region K Units (2020-2025)
  • Table 410. Analgesics Sales Antimigraine Agents , by Region K Units (2020-2025)
  • Table 411. Analgesics Sales Narcotic Analgesics , by Region K Units (2020-2025)
  • Table 412. Analgesics Sales Narcotic analgesics. , by Region K Units (2020-2025)
  • Table 413. Analgesics Sales NSAIDs , by Region K Units (2020-2025)
  • Table 414. Analgesics Sales Others , by Region K Units (2020-2025)
  • Table 415. South America Analgesics Sales, by Country K Units (2020-2025)
  • Table 416. South America Analgesics Sales, by Type K Units (2020-2025)
  • Table 417. South America Analgesics Sales, by Application K Units (2020-2025)
  • Table 418. South America Analgesics Sales, by End User K Units (2020-2025)
  • Table 419. South America Analgesics Sales, by Classes K Units (2020-2025)
  • Table 420. Brazil Analgesics Sales, by Type K Units (2020-2025)
  • Table 421. Brazil Analgesics Sales, by Application K Units (2020-2025)
  • Table 422. Brazil Analgesics Sales, by End User K Units (2020-2025)
  • Table 423. Brazil Analgesics Sales, by Classes K Units (2020-2025)
  • Table 424. Argentina Analgesics Sales, by Type K Units (2020-2025)
  • Table 425. Argentina Analgesics Sales, by Application K Units (2020-2025)
  • Table 426. Argentina Analgesics Sales, by End User K Units (2020-2025)
  • Table 427. Argentina Analgesics Sales, by Classes K Units (2020-2025)
  • Table 428. Rest of South America Analgesics Sales, by Type K Units (2020-2025)
  • Table 429. Rest of South America Analgesics Sales, by Application K Units (2020-2025)
  • Table 430. Rest of South America Analgesics Sales, by End User K Units (2020-2025)
  • Table 431. Rest of South America Analgesics Sales, by Classes K Units (2020-2025)
  • Table 432. Asia Pacific Analgesics Sales, by Country K Units (2020-2025)
  • Table 433. Asia Pacific Analgesics Sales, by Type K Units (2020-2025)
  • Table 434. Asia Pacific Analgesics Sales, by Application K Units (2020-2025)
  • Table 435. Asia Pacific Analgesics Sales, by End User K Units (2020-2025)
  • Table 436. Asia Pacific Analgesics Sales, by Classes K Units (2020-2025)
  • Table 437. China Analgesics Sales, by Type K Units (2020-2025)
  • Table 438. China Analgesics Sales, by Application K Units (2020-2025)
  • Table 439. China Analgesics Sales, by End User K Units (2020-2025)
  • Table 440. China Analgesics Sales, by Classes K Units (2020-2025)
  • Table 441. Japan Analgesics Sales, by Type K Units (2020-2025)
  • Table 442. Japan Analgesics Sales, by Application K Units (2020-2025)
  • Table 443. Japan Analgesics Sales, by End User K Units (2020-2025)
  • Table 444. Japan Analgesics Sales, by Classes K Units (2020-2025)
  • Table 445. India Analgesics Sales, by Type K Units (2020-2025)
  • Table 446. India Analgesics Sales, by Application K Units (2020-2025)
  • Table 447. India Analgesics Sales, by End User K Units (2020-2025)
  • Table 448. India Analgesics Sales, by Classes K Units (2020-2025)
  • Table 449. South Korea Analgesics Sales, by Type K Units (2020-2025)
  • Table 450. South Korea Analgesics Sales, by Application K Units (2020-2025)
  • Table 451. South Korea Analgesics Sales, by End User K Units (2020-2025)
  • Table 452. South Korea Analgesics Sales, by Classes K Units (2020-2025)
  • Table 453. Taiwan Analgesics Sales, by Type K Units (2020-2025)
  • Table 454. Taiwan Analgesics Sales, by Application K Units (2020-2025)
  • Table 455. Taiwan Analgesics Sales, by End User K Units (2020-2025)
  • Table 456. Taiwan Analgesics Sales, by Classes K Units (2020-2025)
  • Table 457. Australia Analgesics Sales, by Type K Units (2020-2025)
  • Table 458. Australia Analgesics Sales, by Application K Units (2020-2025)
  • Table 459. Australia Analgesics Sales, by End User K Units (2020-2025)
  • Table 460. Australia Analgesics Sales, by Classes K Units (2020-2025)
  • Table 461. Rest of Asia-Pacific Analgesics Sales, by Type K Units (2020-2025)
  • Table 462. Rest of Asia-Pacific Analgesics Sales, by Application K Units (2020-2025)
  • Table 463. Rest of Asia-Pacific Analgesics Sales, by End User K Units (2020-2025)
  • Table 464. Rest of Asia-Pacific Analgesics Sales, by Classes K Units (2020-2025)
  • Table 465. Europe Analgesics Sales, by Country K Units (2020-2025)
  • Table 466. Europe Analgesics Sales, by Type K Units (2020-2025)
  • Table 467. Europe Analgesics Sales, by Application K Units (2020-2025)
  • Table 468. Europe Analgesics Sales, by End User K Units (2020-2025)
  • Table 469. Europe Analgesics Sales, by Classes K Units (2020-2025)
  • Table 470. Germany Analgesics Sales, by Type K Units (2020-2025)
  • Table 471. Germany Analgesics Sales, by Application K Units (2020-2025)
  • Table 472. Germany Analgesics Sales, by End User K Units (2020-2025)
  • Table 473. Germany Analgesics Sales, by Classes K Units (2020-2025)
  • Table 474. France Analgesics Sales, by Type K Units (2020-2025)
  • Table 475. France Analgesics Sales, by Application K Units (2020-2025)
  • Table 476. France Analgesics Sales, by End User K Units (2020-2025)
  • Table 477. France Analgesics Sales, by Classes K Units (2020-2025)
  • Table 478. Italy Analgesics Sales, by Type K Units (2020-2025)
  • Table 479. Italy Analgesics Sales, by Application K Units (2020-2025)
  • Table 480. Italy Analgesics Sales, by End User K Units (2020-2025)
  • Table 481. Italy Analgesics Sales, by Classes K Units (2020-2025)
  • Table 482. United Kingdom Analgesics Sales, by Type K Units (2020-2025)
  • Table 483. United Kingdom Analgesics Sales, by Application K Units (2020-2025)
  • Table 484. United Kingdom Analgesics Sales, by End User K Units (2020-2025)
  • Table 485. United Kingdom Analgesics Sales, by Classes K Units (2020-2025)
  • Table 486. Netherlands Analgesics Sales, by Type K Units (2020-2025)
  • Table 487. Netherlands Analgesics Sales, by Application K Units (2020-2025)
  • Table 488. Netherlands Analgesics Sales, by End User K Units (2020-2025)
  • Table 489. Netherlands Analgesics Sales, by Classes K Units (2020-2025)
  • Table 490. Rest of Europe Analgesics Sales, by Type K Units (2020-2025)
  • Table 491. Rest of Europe Analgesics Sales, by Application K Units (2020-2025)
  • Table 492. Rest of Europe Analgesics Sales, by End User K Units (2020-2025)
  • Table 493. Rest of Europe Analgesics Sales, by Classes K Units (2020-2025)
  • Table 494. MEA Analgesics Sales, by Country K Units (2020-2025)
  • Table 495. MEA Analgesics Sales, by Type K Units (2020-2025)
  • Table 496. MEA Analgesics Sales, by Application K Units (2020-2025)
  • Table 497. MEA Analgesics Sales, by End User K Units (2020-2025)
  • Table 498. MEA Analgesics Sales, by Classes K Units (2020-2025)
  • Table 499. Middle East Analgesics Sales, by Type K Units (2020-2025)
  • Table 500. Middle East Analgesics Sales, by Application K Units (2020-2025)
  • Table 501. Middle East Analgesics Sales, by End User K Units (2020-2025)
  • Table 502. Middle East Analgesics Sales, by Classes K Units (2020-2025)
  • Table 503. Africa Analgesics Sales, by Type K Units (2020-2025)
  • Table 504. Africa Analgesics Sales, by Application K Units (2020-2025)
  • Table 505. Africa Analgesics Sales, by End User K Units (2020-2025)
  • Table 506. Africa Analgesics Sales, by Classes K Units (2020-2025)
  • Table 507. North America Analgesics Sales, by Country K Units (2020-2025)
  • Table 508. North America Analgesics Sales, by Type K Units (2020-2025)
  • Table 509. North America Analgesics Sales, by Application K Units (2020-2025)
  • Table 510. North America Analgesics Sales, by End User K Units (2020-2025)
  • Table 511. North America Analgesics Sales, by Classes K Units (2020-2025)
  • Table 512. United States Analgesics Sales, by Type K Units (2020-2025)
  • Table 513. United States Analgesics Sales, by Application K Units (2020-2025)
  • Table 514. United States Analgesics Sales, by End User K Units (2020-2025)
  • Table 515. United States Analgesics Sales, by Classes K Units (2020-2025)
  • Table 516. Canada Analgesics Sales, by Type K Units (2020-2025)
  • Table 517. Canada Analgesics Sales, by Application K Units (2020-2025)
  • Table 518. Canada Analgesics Sales, by End User K Units (2020-2025)
  • Table 519. Canada Analgesics Sales, by Classes K Units (2020-2025)
  • Table 520. Mexico Analgesics Sales, by Type K Units (2020-2025)
  • Table 521. Mexico Analgesics Sales, by Application K Units (2020-2025)
  • Table 522. Mexico Analgesics Sales, by End User K Units (2020-2025)
  • Table 523. Mexico Analgesics Sales, by Classes K Units (2020-2025)
  • Table 524. Analgesics: by Type(USD/Units)
  • Table 525. Research Programs/Design for This Report
  • Table 526. Key Data Information from Secondary Sources
  • Table 527. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Analgesics: by Type USD Million (2014-2019)
  • Figure 5. Global Analgesics: by Application USD Million (2014-2019)
  • Figure 6. Global Analgesics: by End User USD Million (2014-2019)
  • Figure 7. Global Analgesics: by Classes USD Million (2014-2019)
  • Figure 8. South America Analgesics Share (%), by Country
  • Figure 9. Asia Pacific Analgesics Share (%), by Country
  • Figure 10. Europe Analgesics Share (%), by Country
  • Figure 11. MEA Analgesics Share (%), by Country
  • Figure 12. North America Analgesics Share (%), by Country
  • Figure 13. Global Analgesics: by Type K Units (2014-2019)
  • Figure 14. Global Analgesics: by Application K Units (2014-2019)
  • Figure 15. Global Analgesics: by End User K Units (2014-2019)
  • Figure 16. Global Analgesics: by Classes K Units (2014-2019)
  • Figure 17. South America Analgesics Share (%), by Country
  • Figure 18. Asia Pacific Analgesics Share (%), by Country
  • Figure 19. Europe Analgesics Share (%), by Country
  • Figure 20. MEA Analgesics Share (%), by Country
  • Figure 21. North America Analgesics Share (%), by Country
  • Figure 22. Global Analgesics: by Type USD/Units (2014-2019)
  • Figure 23. Global Analgesics share by Players 2019 (%)
  • Figure 24. Global Analgesics share by Players (Top 3) 2019(%)
  • Figure 25. Global Analgesics share by Players (Top 5) 2019(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 31. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2019
  • Figure 33. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc (United States) Revenue: by Geography 2019
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2019
  • Figure 37. Reckitt Benckiser (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. Reckitt Benckiser (United Kingdom) Revenue: by Geography 2019
  • Figure 39. Endo Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 40. Endo Pharmaceuticals (Ireland) Revenue: by Geography 2019
  • Figure 41. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 42. Bristol-Myers Squibb (United States) Revenue: by Geography 2019
  • Figure 43. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 45. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 46. Sanofi (France) Revenue: by Geography 2019
  • Figure 47. Global Analgesics: by Type USD Million (2020-2025)
  • Figure 48. Global Analgesics: by Application USD Million (2020-2025)
  • Figure 49. Global Analgesics: by End User USD Million (2020-2025)
  • Figure 50. Global Analgesics: by Classes USD Million (2020-2025)
  • Figure 51. South America Analgesics Share (%), by Country
  • Figure 52. Asia Pacific Analgesics Share (%), by Country
  • Figure 53. Europe Analgesics Share (%), by Country
  • Figure 54. MEA Analgesics Share (%), by Country
  • Figure 55. North America Analgesics Share (%), by Country
  • Figure 56. Global Analgesics: by Type K Units (2020-2025)
  • Figure 57. Global Analgesics: by Application K Units (2020-2025)
  • Figure 58. Global Analgesics: by End User K Units (2020-2025)
  • Figure 59. Global Analgesics: by Classes K Units (2020-2025)
  • Figure 60. South America Analgesics Share (%), by Country
  • Figure 61. Asia Pacific Analgesics Share (%), by Country
  • Figure 62. Europe Analgesics Share (%), by Country
  • Figure 63. MEA Analgesics Share (%), by Country
  • Figure 64. North America Analgesics Share (%), by Country
  • Figure 65. Global Analgesics: by Type USD/Units (2020-2025)
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline PLC (United Kingdom)
  • Pfizer Inc (United States)
  • Johnson & Johnson (United States)
  • Reckitt Benckiser (United Kingdom)
  • Endo Pharmaceuticals (Ireland)
  • Bristol-Myers Squibb (United States)
  • Eli Lilly and Company (United States)
  • Sanofi (France)
Additional players considered in the study are as follows:
Allegiant Health , DME Company LLC , Gemini Pharmaceuticals
Select User Access Type

Key Highlights of Report


Nov 2020 226 Pages 74 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Analgesics Market research Quantitative research analysis
Global Analgesics Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Analgesics Market research Report?

Have a Query? Click Here

Other Related Reports

Dexamethasone Acetate Comprehensive Study by Application (Hospitals, Clinics, Home Care, Others), Form (Crystal, Injections, Powder), Distribution Channels (Online Pharmacies, Medical Stores, Hospita...
$ 3650
Clemastine Fumarate Comprehensive Study by Type (1.34 mg, 2.68 mg), Application (Antihistaminic), Distribution Channel (Retail Pharmacies, Online Pharmacies, Others) Players and Region - Global Marke...
$ 3500
Pharmaceutical Glass Packaging Comprehensive Study by Type (Cartridges, Glass Vials, Ampoules, Others), Application (Injectable, Transfusion, Others), Glass types (Type I (Borosilicate glass / Neutra...
$ 3750
Transdermal Drug Delivery System Comprehensive Study by Type (Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches}, Transdermal Semisolids {...
$ 3450
Liquid Bandage Comprehensive Study by Type (Skin Protectants, Tissue Adhesives), Application (Humans, Animals), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Player...
$ 3500
Migraine Drugs Comprehensive Study by Type (Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids}, Preventive Medications {Cardiovascular Drugs, Ant...
$ 3750